Brief: Antengene Receives U.S. FDA Clearance Of IND Application For Phase I Trial Of ATG-017 In Patients With Advanced Solid Tumors
31/10/2022 12:24
Oct 31 (Reuters) - Antengene Corporation Ltd 6996.HK :
* ANTENGENE RECEIVES U.S. FDA CLEARANCE OF IND APPLICATION
FOR
PHASE I TRIAL OF SMALL MOLECULE ERK1/2 INHIBITOR ATG-017 IN
PATIENTS WITH ADVANCED SOLID TUMORS
* ANTENGENE CORP - PLANS TO CONDUCT MULTI-REGIONAL CLINICAL
TRIAL(MRCT) FOR ATG-017 IN CHINA
Source text for Eikon: ID:nPn9tQ42Xa
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106